Expert Commentary
View AllPublications
Integrating Bipolar Disorder Management in Primary Care
Management of sleep apnea in the cleft population
A systematic review of the psychosocial difficulties relevant to patients with migraine
Physical activity promotion in primary care targeting the older adult.
The Direct and Indirect Costs among U.S. Privately Insured Employees with Hypogonadism.
Kilbourne AM, Goodrich DE, O'Donnell AN, Miller CJ. Curr Psychiatry Rep. 2012 Sep 22....
Management of sleep apnea in the cleft population
Muntz HR. Curr Opin Otolaryngol Head Neck Surg. 2012 Sep 20. [Epub ahead of print] ...
A systematic review of the psychosocial difficulties relevant to patients with migraine
Raggi A, Giovannetti AM, Quintas R, D'Amico D, Cieza A, Sabariego C, Bickenbach JE, Leonardi...
Physical activity promotion in primary care targeting the older adult.
Neidrick TJ, Fick DM, Loeb SJ. J Am Acad Nurse Pract. 2012;24:405-16.
Purpose: This...
Purpose: This...
The Direct and Indirect Costs among U.S. Privately Insured Employees with Hypogonadism.
Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R. J...







The Food and Drug Administration Risk Evaluation and Mitigation Strategies on the Use of Opioids: Focus on Education
Douglas C. Throckmorton, MD
Deputy Director
Center for Drug Evaluation and Research
To address the escalating problem of prescription opioid abuse, the Food and Drug Administration (FDA) has developed the risk evaluation and mitigation strategy (REMS) for the use of long-acting opioids. The FDA chose to focus on these drugs because they are involved in a significant proportion of the problems related to aberrant opioid use. Furthermore, placing restrictions on all classes of opioids may have imposed an unnecessary burden on the healthcare system. Nevertheless, the FDA recognizes the dangers presented by the immediate-release opioids abuse and is now developing a separate REMS for these drugs. The goal of both of the REMS is to prevent abuse and minimize misuse of opioids, while ensuring that the patients who benefit from these medicines continue to have access to them. In addition, the FDA partakes in the Analgesic Clinical Trials Innovation, Opportunities, and Networks (ACTION) program -- a joint effort of the government, academia, and pharmaceutical industry to develop new classes of pain medicines.
In this video, Dr. Douglas Throckmorton, Deputy Director of the Center for Drugs Evaluation and Research, provides commentary regarding the use and abuse of opioids, as well as an update on the steps the FDA is taking to prevent it.
References